Patents by Inventor Gary W. Ashley

Gary W. Ashley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9649385
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 16, 2017
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Publication number: 20160271227
    Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 22, 2016
    Applicant: ProLynx LLC
    Inventors: Eric L. SCHNEIDER, Brian HEARN, Gary W. ASHLEY, Daniel V. SANTI
  • Publication number: 20160243106
    Abstract: Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a ?-elimination mechanism.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Eric L. SCHNEIDER
  • Patent number: 9387254
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: July 12, 2016
    Assignee: ProLynx LLC
    Inventors: Daniel V. Santi, Gary W. Ashley
  • Publication number: 20150352246
    Abstract: The invention provides sealants wherein biodegradable hydrogels that do not otherwise comprise protein-reactive groups for binding to membranes or tissue are provided said groups optionally through a linker. The linker may be biodegradable and may be biodegradable by an elimination reaction. The invention also provides multilayer gels for drug delivery wherein a porous gel in contact with a tissue or organ to which the drug is to be delivered is protected by a microporous layer from the surrounding bodily fluid.
    Type: Application
    Filed: January 22, 2014
    Publication date: December 10, 2015
    Applicant: Prolynx LLC
    Inventors: Jeffrey C. HENISE, Gary W. ASHLEY, Daniel V. SANTI
  • Publication number: 20140296476
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Inventors: Daniel V. SANTI, Gary W. ASHLEY
  • Publication number: 20140288190
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.
    Type: Application
    Filed: September 7, 2012
    Publication date: September 25, 2014
    Applicant: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Publication number: 20140256626
    Abstract: Slow release forms of exenatide wherein exenatide is releasably linked to polyethylene glycol carriers are disclosed.
    Type: Application
    Filed: October 17, 2012
    Publication date: September 11, 2014
    Inventors: Daniel V. Santi, Eric L. Schneider, Gary W. Ashley
  • Patent number: 8680315
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: March 25, 2014
    Assignee: Prolynx, LLC
    Inventors: Daniel V. Santi, Gary W. Ashley
  • Publication number: 20110263502
    Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
    Type: Application
    Filed: June 26, 2009
    Publication date: October 27, 2011
    Inventors: Daniel V. Santi, Gary W. Ashley, Brian Hearn
  • Patent number: 7855192
    Abstract: Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism Streptomyces hygroscopicus var. geldanus NRRL 3602, wherein the gene cluster encoding enzymes for the biosynthesis of the natural starter unit 3-amino-5-hydroxybenzoic acid has been deleted.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: December 21, 2010
    Assignee: Kosan Biosciences, Inc.
    Inventors: Gary W. Ashley, Hugo Menzella, Janice Lau Wee, John R. Carney
  • Patent number: 7595300
    Abstract: 15-fluoroketolides of the formula having improved activity and safety, compositions comprising them, and methods for their preparation and use in the treatment of bacterial infections.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: September 29, 2009
    Assignee: Kosan Biosciences Incorporated
    Inventors: Simon James Shaw, Gary W Ashley, Mark A. Burlingame
  • Publication number: 20080188450
    Abstract: Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism Streptomyces hygroscopicus var. geldanus NRRL 3602, wherein the gene cluster encoding enzymes for the biosynthesis of the natural starter unit 3-amino-5-hydroxybenzoic acid has been deleted.
    Type: Application
    Filed: January 23, 2008
    Publication date: August 7, 2008
    Inventors: Gary W. Ashley, Hugo Menzella, Janice Lau Wee, John R. Carney
  • Patent number: 7078233
    Abstract: Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: July 18, 2006
    Assignee: Kosan Biosciences Incorporated
    Inventors: Philip J. Barr, Daniel V. Santi, Gary W. Ashley, Rainer Ziermann
  • Publication number: 20020142400
    Abstract: Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.
    Type: Application
    Filed: May 8, 2001
    Publication date: October 3, 2002
    Inventors: Philip J. Barr, Daniel V. Santi, Gary W. Ashley, Rainer Ziermann
  • Patent number: 6258566
    Abstract: Hybrid and novel polyketide synthases (PKSs) and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo acyl carrier protein (ACP) synthase.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: July 10, 2001
    Assignee: Kosan Biosciences, Inc.
    Inventors: Philip J. Barr, Daniel V. Santi, Gary W. Ashley, Rainer Ziermann
  • Patent number: 6187760
    Abstract: A novel class of cationic phospholipids and novel method for their synthesis are disclosed. The class of phospholipids comprises phosphotriester derivatives of phosphoglycerides and sphingolipids. It has been unexpectedly found that liposomes comprising one or more of these cationic phospholipids are effective in the lipofection of nucleic acids. These novel phospholipids are particularly attractive because of they are not only effective in lipofection, but are extremely cheap and easy to male.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: February 13, 2001
    Assignee: Northwestern University
    Inventors: Gary W. Ashley, Robert C. MacDonald, Miho Shida
  • Patent number: 6033883
    Abstract: Hybrid and novel polyketide synthases and polyketides are produced by use of a multiple vector system. The combinatorial possibilities offered by placing the various catalytic activities of PKS systems on separate vectors permits the construction of improved libraries of PKS and polyketides. In addition, polyketides can be produced in hosts that ordinarily do not produce polyketides by supplying, along with an expression system for the desired PKS, an expression system for holo ACP synthase.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: March 7, 2000
    Assignee: KOSAN Biosciences, Inc.
    Inventors: Philip J. Barr, Daniel V. Santi, Gary W. Ashley, Rainer Ziermann
  • Patent number: 5891714
    Abstract: Cationic phospholipids and their use in treating pathogen-associated disease are disclosed. The class of phospholipids comprises the phosphotriester derivatives of phosphoglycerides and sphingolipids. Liposomes comprising one or more of the cationic phospholipids are effective in the lipofection of nuclidic acids and are therefore useful in methods of treating disease.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 6, 1999
    Assignee: Northwestern University
    Inventors: Gary W. Ashley, Robert C. MacDonald, Miho Shida
  • Patent number: 5855910
    Abstract: A novel class of cationic phospholipids and novel method for their synthesis are disclosed. The class of phospholipids comprises phosphotriester derivatives of phosphoglycerides and sphingolipids. It has been unexpectedly found that liposomes comprising one or more of these cationic phospholipids are effective in the lipofection of nucleic acids. These novel phospholipids are particularly attractive because of they are not only effective in lipofection, but are extremely cheap and easy to make.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 5, 1999
    Assignee: Northwestern University
    Inventors: Gary W. Ashley, Robert C. MacDonald, Miho Shida